Pulsenmore Ltd

PLSM

Capitalización de mercado USD 12.2 M

Expanded commercial team to accelerate U.S. growth as demand for accessible prenatal care and federal rural health investments create new opportunities RAMAT GAN, Israel, Oct. 13, 2026 /PRNewswire/ -- Pulsenmore Ltd. (NASDAQ: PLSM) (TASE: PLSM) ("Pulsenmore" or the "Company"), a pioneer in patient-operated home ultrasound technology, today announced the appointment of David Woods as Chief Commercial Officer (CCO), alongside the expansion of its U.S. commercial team, as the Company scales its presence in the U.S. healthcare market.

MHRA registration allows Pulsenmore FC to be marketed across the United Kingdom and Northern Ireland, extending the Company's home ultrasound platform into the UK fertility market where more than 100,000 IVF and fertility treatment cycles were performed in 2024. OMER, Israel, Sept.

The Pulsenmore FC system is designed to enable women undergoing IVF and fertility preservation treatments to self-perform ultrasound scans from home  This registration marks the Company's second product authorized in Europe and its first expansion beyond prenatal care into the broader women's health market OMER, Israel, Sept. 8, 2026 /PRNewswire/ -- Pulsenmore Ltd.

Management to Host Webcast today at 8:30 am ET to discuss Results and Provide Business Update OMER, Israel, Aug. 31, 2026 /PRNewswire/ -- Pulsenmore Ltd. (NASDAQ: PLSM) (TASE: PLSM), a leading innovator in remote maternal-fetal healthcare and home ultrasound solutions, presents the key operational, commercial, regulatory, and technological achievements as well as financial updates for the six month period ended June 30, 2026.

OMER, Israel, Aug. 24, 2026 /PRNewswire/ -- Pulsenmore Ltd. (NASDAQ: PLSM) (TASE: PLSM), a leading innovator in remote maternal-fetal healthcare and home ultrasound solutions, today announces that it will release its financial results and business highlights for the six months ended June 30, 2026 on August 31, 2026 at 8:30 am ET.

The Company's home ultrasound technology will be integrated at Lis Maternity and Women's Hospital at Ichilov, expanding the ability to incorporate at-home ultrasound scans as part of pregnancy monitoring RAMAT GAN, Israel, Aug. 19, 2026 /PRNewswire/ -- Pulsenmore (NASDAQ: PLSM) (TASE: PLSM), a developer of home ultrasound solutions supported by remote medical guidance, today announced the expansion of its activities in Israel. The Company's home ultrasound technology will be integrated at the Lis Maternity and Women's Hospital at Ichilov, a major center for women's and maternity care in Israel, joining other medical centers that already incorporate the technology into pregnancy monitoring pathways.

The new grant brings the total AI grants approved for Pulsenmore over the past month to approximately $1.6 million, supporting two programs with a combined scope of approximately $3.12 million. The program is designed to advance the next generation of home ultrasound through AI-powered real-time ultrasound analysis and dynamic guidance of the image acquisition process, with the goal of improving scan quality and consistency and enabling home ultrasound to be deployed at greater scale.

The program is designed to enable Pulsenmore to develop and clinically validate AI applications that improve clinical workflow efficiency and enhance the scalability of the company's home ultrasound platform. RAMAT GAN, Israel, July 13, 2026 /PRNewswire/ -- Pulsenmore Ltd.

RAMAT GAN, Israel, June 25, 2026 /PRNewswire/ -- Pulsenmore Ltd. (NASDAQ: PLSM) (TASE: PLSM), a pioneer in home ultrasound technology, today announced that it has entered into a securities purchase agreement with a healthcare-focused institutional investor, for the purchase and sale of 1,562,500 ordinary shares (or pre-funded warrants in lieu thereof) and ordinary warrants to purchase up to 1,562,500 ordinary shares in a private placement at a combined purchase price of $4.80 per ordinary share and accompanying warrant  (or $4.7999 per pre-funded warrant and accompanying ordinary warrant), representing a premium to the Nasdaq Minimum Price under Nasdaq rules.

FDA-authorized home ultrasound technology to be integrated into Ouma Health's virtual maternity care model, creating a scalable pathway to expand the adoption of home ultrasound in prenatal care across the United States RAMAT GAN, Israel, June 24, 2026 /PRNewswire/ -- Pulsenmore Ltd. (NASDAQ: PLSM) (TASE: PLSM), a pioneer in home ultrasound technology, today announced a strategic partnership with Ouma Health, a leading provider of virtual maternity care solutions in the United States.